Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

David M. Nanus, MD
Published: Wednesday, Jul 06, 2016


David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses unanswered questions that remain with atezolizumab (Tecentriq) regarding the treatment of patients with metastatic urothelial carcinoma (mUC).

One of the biggest remaining questions with atezolizumab is finding a biomarker to determine which patients are most likely to respond to the agent, Nanus explains. More than one biomarker will likely be needed, he adds.

Additionally, the duration of treatment with atezolizumab has not yet been determined.

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses unanswered questions that remain with atezolizumab (Tecentriq) regarding the treatment of patients with metastatic urothelial carcinoma (mUC).

One of the biggest remaining questions with atezolizumab is finding a biomarker to determine which patients are most likely to respond to the agent, Nanus explains. More than one biomarker will likely be needed, he adds.

Additionally, the duration of treatment with atezolizumab has not yet been determined.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x